HPV vaccine reduces abnormal pap test resultsMarch 10, 2008Finding signals GARDASIL will spare thousands a diagnosis of cell abnormality that may lead to more tests and possibly surgery BIRMINGHAM, Ala. - A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB). The findings show the vaccine, named GARDASIL, appears to prevent the development of cell changes that lead to cervical disease, the researcher said.
In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine. The 43 percent reduction was for tests that found pre-cancerous changes called high-grade squamous intraepithelial lesions (HSIL) more than three years after women were given the vaccine. GARDASIL reduced other abnormal Pap results, including milder pre-malignant cell changes, by 16 to 35 percent compared to women not given the vaccine. While the findings are not definitive that GARDASIL prevents cancer, they do signal the vaccine will spare thousands of women a diagnosis of cell abnormality or malignant changes that may lead to more tests and possibly surgery, said Warner Huh, M.D., associate professor in the UAB Division of Gynecologic Oncology and the doctor chosen to present the data. "Clearly the vaccine's benefits include something that can be appreciated by women and daughters fairly quickly," Huh said. "This is a positive first sign, and it will take many more years to know definitively if the vaccine prevents cancer." The findings were presented March 10 at the annual meeting of the Society of Gynecological Oncologists held in Tampa. The results are a compilation of three separate trials involving more than 18,000 women, ages 16 to 26, in the United States, Europe and Asia. All test subjects had normal Pap smear readings at the start of the trial. In addition to the drop in unwanted Pap results, the study found invasive procedures like cervical biopsies were performed up to 42 percent less in GARDASIL recipients compared to women not given the vaccine, Huh said. GARDASIL is approved to fight the human papilloma virus (HPV) strains believed to cause 70 percent of cervical cancers and more than 90 percent of genital warts. For many unvaccinated women HPV infections clear up naturally without causing any cervical problems, as do many pre-malignant lesions. In other cases, HPV prompts cell changes that can gradually put women at greater risk of cervical cancer. Nearly 25 million U.S. women between the ages of 14 and 59 are infected with HPV, and the annual cost of screening and treating cervical abnormalities is about $4 billion, according to a statement from the Society of Gynecologic Oncologists. "Dr. Huh's study concludes that the trials covered in this paper indicate an overall benefit of vaccination," the society's statement said. University of Alabama at Birmingham | |||||||||||||||||||||
|
Related HPV Vaccine Current Events and HPV Vaccine News Articles Higher anaphylaxis rates after HPV vaccination: CMAJ study The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was significantly higher - 5 to 20 fold - than that identified in comparable school-based vaccination programs. Mothers less likely to pursue HPV vaccination for youngest daughters Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve mom's acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study. HPV is a sexually transmitted virus known to cause cervical cancer. A missed shot: The failure of HPV vaccination state requirements In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues. Cervical cancer screening: Too many are left unprotected The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened. HPV vaccine does not appear to be effective for treating pre-existing HPV infection For women with human papillomavirus (HPV) infection, use of the HPV-16/18 vaccine will not accelerate reduction of the virus and should not be used to treat the infection, according to a study in the August 15 issue of JAMA. Worldwide distribution of cervical cancer virus is consistent with vaccine targets The variety of human papilloma viruses that cause invasive cervical cancer cases worldwide are largely consistent across continents, according to a new study from the University of North Carolina at Chapel Hill. International studies show high efficacy for HPV vaccine A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer—strains 16 and 18. Study shows continued success for new HPV vaccine against virus responsible for cervical cancer A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer. Girls born with HIV infection at higher risk for cervical problems A generation of children born with HIV are now coming of age and reaching sexual maturity. Girls in this group who are sexually active are experiencing a higher number than expected of cervical abnormalities, a new study finds. HPV infection common among females in US Data from a national study suggests that about one in four U.S. females between the ages of 14 and 59 years may have the sexually transmitted infection human papillomarivus (HPV), according to a study in the February 28 issue of JAMA. More HPV Vaccine Current Events and HPV Vaccine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||